{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:49:23Z","timestamp":1770817763913,"version":"3.50.1"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI123036"],"award-info":[{"award-number":["P01AI123036"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI121430"],"award-info":[{"award-number":["R01AI121430"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,10,20]]},"abstract":"<jats:p>\n            Multidrug therapy is often required. Examples include antiviral therapy, nosocomial infections, and, most commonly, anti-\n            <jats:named-content content-type=\"genus-species\">Mycobacterium tuberculosis<\/jats:named-content>\n            therapy. Our laboratory previously identified a mathematical approach to identify 2-drug regimens with a synergistic or additive interaction using a full factorial study design. Our objective here was to generate a method to identify an optimal 3-drug therapy. We studied\n            <jats:named-content content-type=\"genus-species\">M. tuberculosis<\/jats:named-content>\n            isolate H37Rv in log-phase growth in flasks.\n          <\/jats:p>","DOI":"10.1128\/aac.01610-20","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T14:04:33Z","timestamp":1599055473000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Building Optimal Three-Drug Combination Chemotherapy Regimens"],"prefix":"10.1128","volume":"64","author":[{"given":"G. L.","family":"Drusano","sequence":"first","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Neely","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Children\u2019s Hospital of Los Angeles, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-0735","authenticated-orcid":false,"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter M.","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Children\u2019s Hospital of Los Angeles, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Duncanson","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Nole","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nino","family":"Mtchedlidze","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7052","authenticated-orcid":false,"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"Division Head for the Translational Research Division, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Louie","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101311"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu603"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15007-2"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01682-18"},{"key":"e_1_3_2_6_2","first-page":"503","article-title":"The arrangement of field experiments","volume":"33","author":"Fisher R","year":"1926","unstructured":"Fisher R. 1926. The arrangement of field experiments. J Ministry Agric 33:503\u2013513.","journal-title":"J Ministry Agric"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.04.034"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01695-18"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00106-09"},{"key":"e_1_3_2_11_2","volume-title":"Avelox (moxifloxacin hydrochloride) tablets, package insert","author":"Bayer","year":"1999","unstructured":"Bayer. 1999. Avelox (moxifloxacin hydrochloride) tablets, package insert. Bayer, Whippany, NJ."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01418-13"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.2.181"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4688.1073"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00913-17"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03822-14"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00334-06"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01741-15"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00720-11"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00849-10"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00414-06"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00139-10"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3791\/55559"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3937"},{"key":"e_1_3_2_25_2","volume-title":"Susceptibility testing for mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed, document A24-A","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Susceptibility testing for mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed, document A24-A. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1109\/CBMS.2001.941750"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31825c4ba6"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00856-18"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01610-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01610-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:34:05Z","timestamp":1645479245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01610-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10,20]]}},"alternative-id":["10.1128\/AAC.01610-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01610-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"2020-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01610-20"}}